"Building functional materials for health care and pharmacy from microfluidic principaples and Flow Focusing"
About Ingeniatrics
Monday, 09 September 2013 13:06

The publishing company Elservier has recently published the paper "Building functional materials for health care and pharmacy form microfluidic principles and Flow Focusing",  on the section of Advances Drug Delivery Reviews. As authors:

A.M. Gañán-Calvo, J.M. Montanero, L. Marín-Banderas, M. Flores-Mosquera.


In this review, we aim at establishing a relationship between the fundamentals of the microfluidics technologies used in the Pharmacy field, and the achievements accomplished by those technologies. We describe the main methods for manufacturing micrometer drops, bubbles, and capsules, as well as the corresponding underlying physical mechanisms. In this regard, the review intended to show non-specialist readers the dynamical processes which determine the success of microfluidics techniques. Flow Focusing (FF) is a droplet-based method widely used to produce different types of fluid entities on a continuous basis by applying an extensional coflow. We take this technique as an example to illustrate how microfluidics technologies for drug delivery are progressing from a deep understanding of the physics of fluids involved. Specifically, we describe the limitations of FF, and review novel methods which enhance its stability and robustness. In the last part of this paper, we review some of the accomplishments of microfluidics when it comes to drug manufacturing and delivery. Special attention is paid to the production of the microencapsulated form because this fluidic structure gathers the main functionalities sought for in Pharmacy. We also show how FF has been adapted to satisfy an ample variety of pharmaceutical requirements to date.

To read the hole paper an download it for free until January 2014, please click here.

TargetFish project counts on Ingeniatrics
About Ingeniatrics
Thursday, 04 July 2013 11:28

New and better vaccines to try to prevent disease outbreaks in farmed fish are the aims of a newly launched €6M research partnership. European aquaculture production provides work for around 65,000 people and has a turnover of € 3 billion. However infectious fish diseases can impact on plans to increase production and in some instances no effective treatments are available. The best method for disease control - both on economical and ethical grounds - is disease prevention by vaccination.

TargetFish brings together leading European research groups that are experts on the fish immune system and enterprises from the Biotech and Veterinary sectors to advance the development of existing (but not sufficient) and new prototype vaccines against socio-economically important viral or bacterial pathogens of Atlantic salmon, rainbow trout, common carp, sea bass, seabream and turbot. To achieve the challenging tasks, the project brings together 30 partners from 13 countries, amount them Ingeniatrics.

The role of Ingeniatrics, represented by our R&D director María Flores, is to participate in the microencapsulation of different fish vaccines for oral or immersion vaccination in alginate derivatives.

TargetFish is a large collaborative project funded by the European Commission under the 7th Framework Programme for Research and Technological Development. The estimated duration of the project is from october 2012 to september 2017.

To know more about this project, please click here

Ingeniatrics at the TV programme "Espacio Empresa"
About Ingeniatrics
Friday, 14 June 2013 09:38

On Saturday June 8 was broadcasted in TVE 2, at the programme "Espacio Empresa", a report dedicated to reviewing Ingeniatrics business development, as well as the achievements made so far and future projects.

Ingeniatrics has established itself as a leading company in micro-encapsulation technologies, offering services tailored to the needs of its client in a wide range of business sectors, ranging from agri-food, to the pharmaceutical, environmental, biotechnological or health care industry, among others.

To watch the video click here

Ingeniatrics receives a new investment
About Ingeniatrics
Thursday, 06 June 2013 11:00

After the initial investment approved in early 2011, Ingeniatrics receives a new injection of capital to guarantee scaling success and move forward from laboratory to the pre-industrial scale processes, and thereby to carry out our definitive industrial scale expansion and development of our Flow Focusing ® Microencapsulation plant scaling.

With the aim of positioning Ingeniatrics as a leading company in the development of microfluidic technology and associated technologies for Pharma, Biotech and Fine Chemicals, the Jeremie venture capital fund, managed by Invercaria SGCR; Caixa Capital Risc, La Caixa's Private Equity subsidiary and the Reference Shareholders have made a second fund-raising. They have become to rely on our project and give us a push over to the achievement of our goals.

Ingeniatrics has validated its Flow Focusing technology with several world-class leading companies, going from companies in the area of consumer goods, to pharmaceuticals, biotechnology industry and fine chemicals.

Quality and Environmental Audit
About Ingeniatrics
Wednesday, 15 May 2013 12:00

On February 14th took place in Ingeniatrics the first Follow-up Quality and Environmental Systems Audit, implanted in our company in March 2012. Upon completion, we are pleased to inform you that the result has been "Compliance Evaluation", detecting only some minor non-conformities that are already solved.

The good result obtained is mainly due to all our daily efforts in matching products to the customers´ expectations, taking into account both their demands and the market specifications, as well as our staff suggestions. We provide the necessary human and material resources for achieving the goals marked at all times.

Equally, Ingeniatrics have a firm commitment with preventing or, where the case, minimizing environmental pollution, promoting the reduction and recycling of materials whenever possible. We take all necessary protective measures to prevent accidental releases to the environment, incluidng leaks and spills of machinery and equipment. We make sure to promote environmental awareness and training of each member of the company, as well as contractors, through continuous training to ensure that all the work is performed in a way that respects the environment. For that we use the best a available technologies that allow us to reduce the environmental impacts of our business.
Ingeniatrics takes part in technological project SCALEPROT
About Ingeniatrics
Monday, 08 April 2013 11:15

The therapeutic recombinant protein production has changed the way we see modern medicine, contributing to the creation of innovative and effective therapies against chronic diseases, with emphasis on neoplasics and degenerative diseases. Therefore, in recent years, the use of therapeutic peptides and proteins in human and veterinary medicine have increased sharply; actually the 50% of the new molecules approved by the FDA for clinical research have a biotechnological origin. The global market of biopharmaceuticals for human use has now reached 30,000 million dollars and is expected to double in the coming years.

SCALEPROT was born with the prospect of covering a high demand market. The aim of the project was the research and development of new ways of scaling preindustrial exclusive innovative technologies coming from companies such as Ingeniatrics, Biomedal, Bionaturis and Infarmade, in order to train them in the production and development of therapeutic recombinant proteins under quality standards.

This way it has been successfully achieved the increase of the capacity of the mentioned companies to offer products and services CRO and CMO of a higher value for the biopharmaceutical industry, including the possibility of offering more integrated services from some of the participating companies. It was also intended to develop technologies for production, formulation and analysis of candidate molecules to be used in the pharmaceutical industry as well as purification systems, or as candidate therapeutic molecules to pass clinical phase.

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 2 of 20